Hsp90 molecular chaperone inhibitors: are we there yet?

L Neckers, P Workman - Clinical cancer research, 2012 - aacrjournals.org
Heat shock protein (Hsp) 90 is an ATP-dependent molecular chaperone that is exploited by
malignant cells to support activated oncoproteins, including many cancer-associated …

HSP90 and the chaperoning of cancer

L Whitesell, SL Lindquist - Nature Reviews Cancer, 2005 - nature.com
Standing watch over the proteome, molecular chaperones are an ancient and evolutionarily
conserved class of proteins that guide the normal folding, intracellular disposition and …

[HTML][HTML] Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

BD Lehmann, JA Bauer, X Chen, ME Sanders… - The Journal of clinical …, 2011 - jci.org
Intratumor heterogeneity is a major clinical problem because tumor cell subtypes display
variable sensitivity to therapeutics and may play different roles in progression. We previously …

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

A Kamal, L Thao, J Sensintaffar, L Zhang, MF Boehm… - Nature, 2003 - nature.com
Abstract Heat shock protein 90 (Hsp90) is a molecular chaperone that plays a key role in the
conformational maturation of oncogenic signalling proteins, including HER-2/ErbB2, Akt, Raf …

Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/p21WAF1/CIP1 and p27KIP1 pathway

SK Singh, S Banerjee, EP Acosta, JW Lillard… - Oncotarget, 2017 - pmc.ncbi.nlm.nih.gov
Resveratrol (RES) is the most effective natural products used for the treatment of a variety of
cancers. In this study, we tested the effect of RES in enhancing the efficacy of docetaxel …

Targeting the cell cycle: a new approach to cancer therapy

GK Schwartz, MA Shah - Journal of clinical oncology, 2005 - ascopubs.org
The cell cycle represents a series of tightly integrated events that allow the cell to grow and
proliferate. Critical parts of the cell cycle machinery are the cyclin-dependent kinases …

HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer …

S Modi, A Stopeck, H Linden, D Solit… - Clinical Cancer …, 2011 - aacrjournals.org
Purpose: HSP90 is a chaperone protein required for the stability of a variety of client
proteins. 17-Demethoxygeldanamycin (17-AAG) is a natural product that binds to HSP90 …

Hsp90 inhibitors as novel cancer chemotherapeutic agents

L Neckers - Trends in molecular medicine, 2002 - cell.com
Abstract Heat shock protein 90 (Hsp90) is a molecular chaperone whose association is
required for the stability and function of multiple mutated, chimeric and over-expressed …

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

SA Eccles, A Massey, FI Raynaud, SY Sharp… - Cancer …, 2008 - aacrjournals.org
We describe the biological properties of NVP-AUY922, a novel resorcinylic isoxazole amide
heat shock protein 90 (HSP90) inhibitor. NVP-AUY922 potently inhibits HSP90 (K d= 1.7 …

Heat shock protein 90 as a molecular target for cancer therapeutics

JS Isaacs, W Xu, L Neckers - Cancer cell, 2003 - cell.com
Cancer is a disease characterized by genetic instability. Although identification of novel
therapeutic agents via molecular targeting offers the promise of great specificity coupled with …